Triazole antifungals are useful in the treatment of Aspergillus disease and these drugs have side effects which clinicians should be aware of. Posaconazole is an orally administered second-generation triazole antifungal agent which inhibits lanosterol 14alpha-demethylase, an enzyme that converts lanosterol to ergosterol, a vital component of the fungal cell membrane. Posaconazole has a favorable side effect profile, is safe and well tolerated when compared to the earlier generation of triazole antifungals. Common side effects of posaconazole include gastrointestinal, hepatobiliary, neurological, and skin and subcutaneous disorders. Renal disorders are classed as an uncommon side effect of posaconazole, occurring in ~0.1-1% of patients. We describe 2 episodes of acute kidney injury (AKI) in a Caucasian whose Aspergillus lung disease was being treated with posaconazole. Regular monitoring of renal function may be necessary for patients on posaconazole to facilitate early identification of acute kidney injury which is reversible.
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We describe 2 episodes of acute kidney injury (AKI) in a Caucasian whose Aspergillus lung disease was being treated with posaconazole. Regular monitoring of renal function may be necessary for patients on posaconazole to facilitate early identification of acute kidney injury which is reversible. We describe 2 episodes of acute kidney injury (AKI) in a Caucasian whose Aspergillus We report 2 episodes of AKI attributed to posaconazole therapy in the same patient. Posaconazole is predominantly metabolised and excreted through the liver; renal 89 clearance is a minor elimination pathway. Mild-to-moderate renal impairment has no 90 effect on the pharmacokinetics of posaconazole and thus no dose adjustment is 91 recommended. 5, 11 The oral bioavailability of delayed-release posaconazole tablets is 92 more predictable than that of the liquid suspension and higher plasma levels are 93 achieved with the tablets when compared to the liquid suspension. 12 , It is recommended 94 that serum levels are monitored as some patients may not achieve the desired target.
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However, the highest cut-off to prevent toxicity is not known. Another reason to 
